Revance Therapeutics Inc. (NASDAQ:RVNC) saw a downside of -4.22% to $21.79 after subtracting -$0.96 on Monday. The 5-day average trading volume is 1,192,869 shares of the company’s common stock. It has gained $23.53 in the past week and touched a new high 1 time within the past 5 days. An average of 1,170,512 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,231,753.
RVNC’s 1-month performance is -9.85% or -$2.23 on its low of $21.76 reached on 07/27/23. The company’s shares have touched a 52-week low of $16.47 and high of $37.98, with the stock’s rally to the 52-week high happening on 05/09/23. YTD, RVNC has achieved 18.04% or $3.48 and has reached a new high 13 times. However, the current price is down -42.63% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
RVNC stock investors last saw insider trading activity on Aug 03.Foley Mark J (CEO) most recently sold 26,279 shares at $22.57 per share on Aug 03. This transaction cost the insider $593,151. CEO, Foley Mark J, sold 26,279 shares at a price of $24.94 on Jul 03. Then, on Jul 03, CFO Schilke Tobin sold 1,701 shares at a price of $25.04 per share. This transaction amounted to $42,593.
Valuation Metrics
RVNC stock has a beta of 0.77. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 11.82.
Revance Therapeutics Inc.’s quick ratio for the period ended March 30 was 3.80, with the current ratio over the same period at 4.10. In terms of profitability, the gross margin trailing 12 months is 61.70%. The trailing 12-month EBITDA margin is -179.86%. The firm’s gross profit as reported stood at $80.9 million against revenue of $132.56 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Revance Therapeutics Inc.’s cash and short-term investments amounted to $137.27 million against total debt of $435.72 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -7.61% to -$59.79 million, while revenue of -$145.95 million was -144.1% off the previous quarter. Analysts expected RVNC to announce -$0.7 per share in earnings in its latest quarter, but it posted -$0.74, representing a -5.70% surprise. EBITDA for the quarter stood at more than -$52.65 million. RVNC stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 574.47 million, with total debt at $435.72 million. Shareholders hold equity totaling $84.04 million.
Let’s look briefly at Revance Therapeutics Inc. (RVNC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 39.34% to suggest the stock is trending Neutral, with historical volatility in this time period at 58.30%.
The stock’s 5-day moving average is $22.56, reflecting a -7.15% or -$1.69 change from its current price. RVNC is currently trading -11.39% above its 20-day SMA, -25.63% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -30.37% and SMA200 by-13.14%.
Stochastic %K and %D was 25.83% and 27.94% and the average true range (ATR) pointed at 1.10. The RSI (14) points at 38.25%, while the 14-day stochastic is at 5.79% with the period’s ATR at 1.09. The stock’s 9-day MACD Oscillator is pointing at -0.14 and -0.15 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Revance Therapeutics Inc. (NASDAQ: RVNC), Morgan Stanley launched coverage with an Equal-weight rating. Analysts offering their rating for RVNC stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate RVNC as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 9 have offered a “buy” rating.
What is RVNC’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $21.00 and a high of $65.00, with their median price target at $41.00. Looking at these predictions, the average price target given by analysts is for Revance Therapeutics Inc. (RVNC) stock is $40.67.
